1. Home /
    2. Altai Protocol Library /
  2. New Drug:  Futibatinib for cholangiocarcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug:  Futibatinib for cholangiocarcinoma

New Drug:  Futibatinib for cholangiocarcinoma
Study:
  • A single-arm, multicenter, phase 2 study
  • Advanced/metastatic unresectable iCCA harboring FGFR2 gene fusions
  • Disease progression after ≥1 line of systemic therapy
  • Futibatinib 20 mg QD until disease progression/unacceptable toxicity ( n=103)
Efficacy:
  • ORR: 42 % [32.0-52.0]
  • mDoR: 9.7 mos [7.6-17.1 mos]
Safety:
  • Any grade AEs: hyperphosphatemia (79.1%), diarrhea (37.3%), dry mouth (32.8%)
  • Grade ≥3 AEs: hyperphosphatemia (25.4%)
  • Treatment related death: 2 patients

Goyal L, Meric-Bernstam F

Goyal L, Meric-Bernstam F et al. A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma?utm_medium=email&utm_source=govdelivery

Reviewed by Elvin CHALABİYEV, MD on Jan 30, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More